Drug Trial Radar · NCT01944852
Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.
Last checked: Nov 20, 2026Latest source record: Nov 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Mar 2013
Primary completion
Feb 28, 2020
Study completion Feb 28, 2020
Sponsor
- Lead sponsor
- Pr Eric GoffinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DIDo study is an open-label, randomised, multicentre study with 2 parallel groups in incident CAPD patients aged of 65 at minimum : * One group in which patients will receive 2 bags of icodextrin/day and 1 bag of glucose * One group in which patients will receive 1 bag of icodextrin/day and 2 bags of glucose.
Conditions
- Renal Insufficiency
Interventions
IcodextrinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients stopping 3 bags / dayTime frame: During the treatment phase of 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.